CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic™ has completed the first phase of its ongoing collaboration with AbbVie. During this first discovery phase of the collaboration Synlogic has identified Synthetic Biotic™ leads for the treatment of inflammatory bowel disease (IBD), including Crohn’s Disease and colitis, using the company’s proprietary discovery and development technology platform. Based on the terms of the agreement, Synlogic will receive an undisclosed milestone payment and the companies will move into the second phase of the collaboration. Synlogic is pioneering the development of a novel class of living medicines – Synthetic Biotic™ medicines, which perform critical functions or deliver therapeutic factors to compensate for what is missing or damaged due to disease.
“The delivery of these investigational Synthetic Biotic medicines, as part of the first phase of our collaboration with AbbVie, demonstrates the continued potential of our discovery and development platform against a wide range of diseases,” said Jose Carlos Gutierrez-Ramos, Ph.D., president and chief executive officer of Synlogic. “We believe our living medicines have the potential to be transformational for patients, and our commitment to advance the platform’s power includes pursuing innovative partnerships such as the one we’ve forged with AbbVie.”
Under the terms of the ongoing research and development collaboration, AbbVie and Synlogic will continue to evaluate the investigational Synthetic Biotic leads as potential candidates for the treatment of IBD and advance them through preclinical development, with AbbVie having a right to subsequent clinical development and worldwide marketing of resulting products. Further detail on the terms of the deal were not disclosed.
About the Synthetic Biotic™ Platform
Synlogic has developed
a proprietary drug discovery and development platform for creation of an
innovative new class of living medicines called Synthetic Biotics. The
company deploys the tools and principles of synthetic biology to
genetically reengineer beneficial, probiotic microbes to perform
critical functions missing or damaged due to disease. Once engineered,
Synthetic Biotic medicines are capable of “replacing” what a patient’s
body cannot do with their own somatic organs due to their disease state,
such as producing or consuming an enzyme or protein critical to health.
These living medicines can be designed to dynamically sense and respond
to their environment for a tailored effect and can also function
catalytically where a single engineered cell can carry out multiple
cycles of the intended pathway activity. Synlogic is developing
Synthetic Biotic medicines for rare metabolic disease and actively
seeking new partnership opportunities for more common disorders.
About Synlogic™
Synlogic™ is pioneering the development of a
novel class of living medicines, Synthetic Biotics™, based on its
proprietary drug discovery and development platform. Synlogic’s initial
pipeline includes Synthetic Biotic medicines for the treatment of rare
genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria
(PKU). In addition, the company is leveraging the broad potential of its
platform to create Synthetic Biotic medicines for the treatment of more
common diseases, including liver disease, inflammatory and immune
disorders, and cancer. Synlogic is collaborating with AbbVie to develop
Synthetic Biotic-based treatments for inflammatory bowel disease (IBD).
For more information, please visit synlogictx.com.
Forward-Looking Statements
This press release contains
“forward-looking statements” that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release regarding
strategy, future operations, future financial position, future revenue,
projected expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this press
release, the words “may,” “could,” “should,” “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “plan,” “predict” and similar
expressions and their variants, as they relate to Synlogic may identify
forward-looking statements. Examples of forward-looking statements,
include, but are not limited to, statements regarding the potential of
Synlogic’s platform to develop therapeutics to address a wide range of
diseases, including IBD, and the continued preclinical development of
Synthetic Biotic leads pursuant to the AbbVie collaboration. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors, including, the
uncertainties inherent in the preclinical development process, the
ability of Synlogic to protect its intellectual property rights and
legislative, regulatory, political and economic developments.